Evaluation of the Medical Treatment of Acromegaly (About 15 Cases)

Abstract

Acromegaly is a condition caused by an excessive secretion of growth hormone due to a somatotropic pituitary adenoma, leading to an acquired dysmorphic syndrome. The aim of this study is to evaluate the effectiveness and tolerance of medical treatment using Lanreotide LP 120 mg in 15 patients with acromegaly, who were followed up at the endocrinology department of Ibn Sina Hospital in Rabat between 2017 and 2018. The quality of life of the patients after Lanreotide treatment was evaluated using the AcroQol questionnaire. 80% of the patients were found to have acrofacial dysmorphic syndrome, with the diagnosis based on clinical, biological, and radiological data. Magnetic resonance imaging revealed a pituitary macroadenoma in 86.7% of the cases. All patients were treated with medical treatment using Lanreotide LP 120mg. Fourteen patients underwent adenomectomy, with 4 of them receiving GammaKnife radiotherapy. During treatment, complications were observed in 80% of patients, with half of them related to vesicular lithiasis. The AcroQol scores obtained in the study were less satisfactory than expected, indicating a lower quality of life compared to the general population.